title: Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater.
abstract: Carcinomas of the ampulla of Vater are rare and assumed to generally arise from preexisting adenomas (adenoma-carcinoma sequence). Histologically, distinct subtypes can be distinguished that were shown to differ significantly in terms of clinical outcome. Since pathologists usually receive bioptic tissue samples of ampullary tumors obtained during endoscopy, accurate classification of carcinoma subtypes can sometimes be difficult on morphological criteria alone. We therefore performed immunohistochemistry using a panel of established marker proteins (CK7, CK20, p21, p27, ESA, bax, and ephrin-B2) on 175 carcinoma, 111 adenoma, and 152 normal mucosa specimens of the ampulla of Vater and identified distinct immunoprofiles for every carcinoma subtype. Fluorescence in situ hybridization analyses of therapeutic target genes (c-myc, EGFR1, CCND1, HER2) found CCND1 to represent the most frequently amplified gene in our series (7.5%).
authors.affiliation: Institute of Pathology, University of Basel, Schönbeinstrasse 40, 4003 Basel, Switzerland. dbaumhoer@mac.com
authors.forename: Daniel
authors.initials: D
authors.lastname: Baumhoer
authors.forename: Inti
authors.initials: I
authors.lastname: Zlobec
authors.forename: Luigi
authors.initials: L
authors.lastname: Tornillo
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Dietmaier
authors.forename: Peter H
authors.initials: PH
authors.lastname: Wuensch
authors.forename: Arndt
authors.initials: A
authors.lastname: Hartmann
authors.forename: Fausto
authors.initials: F
authors.lastname: Sessa
authors.forename: Petra
authors.initials: P
authors.lastname: Ruemmele
authors.forename: Luigi M
authors.initials: LM
authors.lastname: Terracciano
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014670:Ampulla of Vater / Q000378:metabolism* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D003138:Common Bile Duct Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism*; D036388:Ephrin-B2 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016130:Immunophenotyping; D053554:Keratin-20 / Q000235:genetics / Q000378:metabolism; D053552:Keratin-7 / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D055815:Young Adult; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D019938:Cyclin D1; D036388:Ephrin-B2; D053554:Keratin-20; D053552:Keratin-7; D018809:Proliferating Cell Nuclear Antigen; D016271:Proto-Oncogene Proteins c-myc; D018719:Erb-b2 Receptor Tyrosine Kinases; D051028:bcl-2-Associated X Protein; C530104:CCND1 protein, human; C489427:MYC protein, human; C413374:p27 antigen; C508053:ERBB2 protein, human